Spyre Therapeutics (SYRE)

Spyre Therapeutics LLC • Aeglea Development Company, Inc. • AERase, Inc. • AECase, Inc. • AEMase, Inc. • AE4ase, Inc. • AE5ase, Inc. • AE6ase, Inc. • Aeglea Biotherapeutics UK Limited • Aeglea Ireland Limited ...

SYRE stock data

1M 3M 6M 1Y

Analyst ratings and price targets

Last 3 months

Latest filings (excl ownership)

View all

8-K

Spyre Therapeutics Highlights 2025 Priorities and Robust Pipeline of Upcoming Clinical Readouts

13 Jan 25

8-K

Entry into a Material Definitive Agreement

19 Nov 24

424B5

Prospectus supplement for primary offering

19 Nov 24

424B5

Prospectus supplement for primary offering

18 Nov 24

10-Q/A

2024 Q3

Quarterly report (amended)

18 Nov 24

10-Q/A

2024 Q2

Quarterly report (amended)

18 Nov 24

10-Q/A

2024 Q1

Quarterly report (amended)

18 Nov 24

10-K/A

2023 FY

Annual report (amended)

18 Nov 24

8-K

Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review

18 Nov 24

8-K

SPY001 was well tolerated with a favorable safety profile consistent with the anti-α4β7 class

12 Nov 24

Transcripts

SYRE

Earnings call transcript

2018 Q4

7 Mar 19

Latest ownership filings

View all

MICHAEL THOMAS HENDERSON

14 Jan 25

SC 13G/A

Venrock Healthcare Capital Partners III, L.P.

14 Nov 24

SC 13G/A

PERCEPTIVE ADVISORS LLC

Deep Track Capital, LP

14 Nov 24

SC 13G/A

Avoro Capital Advisors LLC

14 Nov 24

Financial summary

Financial statements Chart SYRE financial data

Quarter (USD)	Sep 24	Jun 24	Mar 24	Dec 23
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 23	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	71.58 mm	71.58 mm	71.58 mm	71.58 mm	71.58 mm	71.58 mm
Cash burn (monthly)	(no burn)	1.69 mm	23.00 mm	18.68 mm	9.81 mm	12.60 mm
Cash used (since last report)	n/a	6.81 mm	92.53 mm	75.12 mm	39.45 mm	50.70 mm
Cash remaining	n/a	64.77 mm	-20.95 mm	-3.54 mm	32.13 mm	20.88 mm
Runway (months of cash)	n/a	38.3	-0.9	-0.2	3.3	1.7

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2024

SYRE institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	123	112	+9.8%
Opened positions	31	30	+3.3%
Closed positions	20	20	–
Increased positions	42	46	-8.7%
Reduced positions	25	17	+47.1%

13F shares	Current	Prev Q	Change
Total value	1.49 tn	1.17 tn	+27.2%
Total shares	63.27 mm	63.32 mm	-0.1%
Total puts	1.30 k	1.50 k	-13.3%
Total calls	600.00	2.60 k	-76.9%
Total put/call ratio	2.2	0.6	+275.6%

Largest owners	Shares	Value	Change
FMR	7.62 mm	$224.22 bn	+1.5%
EcoR1 Capital Fund Qualified	5.00 mm	$2.28 mm	0.0%
Fairmount Funds Management	4.02 mm	$118.17 bn	0.0%
RTW Investments	3.26 mm	$95.83 bn	0.0%
Perceptive Advisors	2.87 mm	$84.48 bn	-5.2%
VR Adviser	2.69 mm	$78.98 bn	0.0%
Venrock Healthcare Capital Partners III	2.69 mm	$91.74 mm	-28.1%
BlackRock	2.66 mm	$78.32 bn	NEW
Lilly Ventures Fund I	2.57 mm	$20.21 mm	0.0%
Vanguard	2.52 mm	$73.99 bn	+31.6%

Largest transactions	Shares	Bought/sold	Change
BlackRock	2.66 mm	+2.66 mm	NEW
BLK BlackRock	0.00	-2.40 mm	EXIT
Paradigm Biocapital Advisors	1.27 mm	+1.27 mm	NEW
Avoro Capital Advisors	598.60 k	-1.24 mm	-67.5%
Assenagon Asset Management	1.14 mm	+1.14 mm	NEW
Venrock Healthcare Capital Partners III	2.69 mm	-1.05 mm	-28.1%
Deep Track Capital	1.00 mm	-756.67 k	-43.1%
GS The Goldman Sachs Group, Inc.	169.31 k	-723.77 k	-81.0%
Wellington Management	1.51 mm	+711.25 k	+89.4%
Farallon Capital Management	0.00	-666.00 k	EXIT

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

SYRE insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
15 Jan 25	Heidy King-Jones	Stock Option Common Stock	Grant	Acquire A	No	No	21.66	95,500	2.07 mm	95,500
15 Jan 25	Turtle Cameron	Stock Option Common Stock	Grant	Acquire A	No	No	21.66	370,000	8.01 mm	370,000
15 Jan 25	Scott L Burrows	Stock Option Common Stock	Grant	Acquire A	No	No	21.66	95,500	2.07 mm	95,500
15 Jan 25	Sheldon Sloan	Stock Option Common Stock	Grant	Acquire A	No	No	21.66	95,500	2.07 mm	95,500
10 Jan 25	Michael Thomas Henderson	Common Stock	Other	Acquire J	No	No	0	105,379	0.00	105,379